CCR2 and adenocarcinoma: In a follow-up study, targeting pSTAT3–CCL2 signaling with C-C chemokine receptor type 2 (CCR2) antagonists reversed the ADT induced cell invasion and macrophage infiltration in transgenic adenocarcinoma of the mouse prostate-C1 (TRAMP-C1) mouse tumors (Lin et al., 2013).